Sumatriptan

Sumatriptan is prescribed to treat:

• Migraine and cluster headaches • Various related conditions in the neurological category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Sumatriptan (Imitrex) is a serotonin 5-HT1B/1D receptor agonist used for acute treatment of migraine and cluster headache. It was the first triptan and remains the most prescribed, and it treats attacks rather than preventing them — a distinction that determines whether a patient needs this drug, a preventive one, or both.

Mechanism of Action

Sumatriptan activates 5-HT1B and 5-HT1D receptors. The 1B receptors sit on cranial blood vessels, where activation produces vasoconstriction, reversing the dilation that accompanies a migraine attack. The 1D receptors sit on trigeminal nerve terminals, where activation inhibits release of vasoactive neuropeptides including CGRP and substance P, reducing the neurogenic inflammation that drives the pain.

The trigeminal effect is now understood to matter more than the vascular one. Migraine is a neurologic disorder involving trigeminovascular activation and central sensitisation rather than simply a vascular event, and the older account of the drug as a cranial vasoconstrictor is incomplete.

That vasoconstrictive activity is not confined to cranial vessels, however, and it is the basis of the cardiovascular contraindications: triptans are not used in coronary artery disease, prior myocardial infarction, prior stroke, uncontrolled hypertension, or Prinzmetal angina.

Timing matters more with triptans than with most analgesics. Once central sensitisation is established — often signalled by cutaneous allodynia, when the scalp or face becomes painful to touch — triptans work considerably less well. Taking one early in an attack is substantially more effective than taking one late, and patients who wait to see whether the headache becomes bad enough to justify it are systematically undertreating themselves.

Clinical Use

Sumatriptan is first-line acute therapy for moderate to severe migraine, and for milder attacks NSAIDs are often sufficient. Combining a triptan with an NSAID such as naproxen is more effective than either alone and is a well-established strategy.

Formulation should match the attack. Oral tablets suit gradual-onset attacks without early vomiting. Subcutaneous injection works within about ten minutes and bypasses the gut entirely, which matters when nausea and gastroparesis prevent absorption — it is also the treatment of choice for cluster headache, where attacks peak within minutes. A nasal spray sits between the two.

Among the triptans, differences are modest but real. Sumatriptan has a relatively short half-life, so headache recurrence within 24 hours is common; naratriptan and frovatriptan act more slowly but last longer and suit patients with recurring or prolonged attacks. Individual response varies enough that failing one triptan does not predict failing another, and trying a second is worthwhile before concluding the class does not work.

The migraine prevention article covers preventive options including CGRP inhibitors, and our neurologic team manages headache that is not responding.

Medication Overuse Headache

The single most important thing for a patient using acute migraine treatment to understand is that using it too often causes headache.

Medication overuse headache develops when acute treatments are taken frequently — roughly ten or more days per month for triptans, combination analgesics, or opioids, or fifteen or more for simple analgesics. It produces a chronic daily headache that is refractory to further acute treatment, and the pattern is self-reinforcing: more headache prompts more medication, which produces more headache.

Patients almost never make this connection themselves, and they often present having escalated their triptan use over months while their headaches have worsened. The treatment is withdrawal of the overused medication, which transiently worsens symptoms before improving them, alongside starting effective prevention.

The practical rule is straightforward: a patient needing acute migraine treatment more than about two days a week needs preventive therapy, not more acute therapy. Tracking headache days and treatment days in a diary makes the pattern visible in a way that recall does not. The American Migraine Foundation covers this in patient-facing terms.

Monitoring and Follow-Up

No laboratory monitoring is required. What should be monitored is frequency of use, headache days per month, and whether the pattern is escalating.

Cardiovascular risk should be assessed before the first prescription and reassessed periodically, since patients treated for migraine over decades accumulate risk factors they did not have at the outset. A patient started on sumatriptan at 35 may be a different cardiovascular proposition at 60.

Triptans are contraindicated within two weeks of an MAO-A inhibitor. Concern about serotonin syndrome with SSRIs and SNRIs is widely cited; the FDA issued an advisory, but subsequent evidence suggests the risk is very low, and the combination is used routinely with awareness rather than avoided. Triptans should not be taken within 24 hours of an ergotamine or another triptan. The MedlinePlus sumatriptan entry covers prescribing detail.

Chest, neck, jaw, or throat tightness or pressure occurs in a minority of patients and is usually not cardiac in origin, but it is unsettling and warrants evaluation the first time it happens rather than assumption.

Special Populations

In older adults, cardiovascular contraindications become more likely to apply, and new-onset headache after 50 warrants investigation rather than empiric migraine treatment — including consideration of temporal arteritis, which is a different and time-critical diagnosis.

In pregnancy, sumatriptan has the most accumulated safety data among triptans and is used when non-drug measures and acetaminophen are inadequate. Migraine often improves during pregnancy. In hemiplegic and basilar migraine, triptans have traditionally been avoided, though this is increasingly questioned. Hepatic impairment reduces clearance of oral formulations.

When to Contact Your Doctor

Seek emergency care for chest pain or pressure that is severe or persistent, sudden severe headache unlike your usual pattern, headache with fever and neck stiffness, headache with weakness, numbness, difficulty speaking, or vision loss, or headache after head injury.

Report headaches that are becoming more frequent, or a need to treat more than about two days a week — that is the point at which prevention should be discussed rather than more acute medication. Report new or changing headache pattern, and any chest, jaw, or throat tightness after a dose.

To discuss preventive treatment, address escalating headache frequency, or review whether a triptan remains appropriate for your cardiovascular risk, contact us or schedule a visit.